ArticleJournal of clinical tuberculosis and other mycobacterial diseases2025
Tuberculosis reactivation in hematopoietic stem cell transplant recipients: a preemptive strategy in an endemic country.
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) remains a global public health issue, particularly in developing countries. Hematopoietic stem cell transplant (HSCT) recipients are at increased risk for TB due to immunosuppression. Methods: This retrospective study (2005-2022) assessed a preemptive latent tuberculosis infection (LTBI) screening and treatment strategy in 338 HSCT recipients and their donors. Screening included tuberculin skin test (TST) or QuantiFERON-TB Gold (QFT), and pulmonary imaging, with positive cases receiving isoniazid (INH) therapy before HSCT. Statistical analyses compared TB reactivation rates, overall survival (OS), and relapse-free survival (RFS) across HSCT groups. Results: Of 338 patients, screening involved TST in 325 and QFT in 13 cases, resulting in 94 (27.8%) patients with LTBI. INH therapy was completed by 83 patients, with 5 discontinuing due to hepatotoxicity. The cumulative incidence of active TB was 0.6%, and one patient who received INH prophylaxis developed LTBI reactivation. LTBI status did not affect OS or RFS. Conclusions: Our study demonstrates that the use of LTBI protocols incorporating TST/QFT and chest CT-scans, followed by INH in positive cases, was safe and is an accessible option among HSCT recipients in high-burden regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.